Novo Nordisk: More Pain On The Horizon

Novo Nordisk (NVO) reported an underwhelming Q2 2025, with revenue growth decelerating to 20.4% YoY and sequential EPS declining, coupled with a downward revision of its FY2025 outlook for revenue, operating profit, and free cash flow. This performance, marked by increased marketing spend, underscores NVO's competitive struggles against Eli Lilly (LLY), which is projected for stronger growth. Despite a recent market cap decline, the company remains significantly overvalued with a forward Price/FCF of 35, leading to a bearish assessment.

Analysis

Novo Nordisk's Q2 2025 results and revised guidance signal a significant deceleration in its growth narrative, driven by intensifying competition and stagnating operational efficiency. YoY revenue growth slowed to 20.4% from 25.9% in the prior quarter, while sequential revenue growth was a marginal 1.4%, a stark contrast to the nearly 6% achieved in the same period of 2024. More concerning is the sequential decline in EPS from $0.99 to $0.93 despite revenue growth, which, coupled with a 15% increase in sales and distribution costs, points to margin compression as the company boosts promotional spending to defend its market position against Eli Lilly (LLY). The competitive pressure is acute, with LLY projected to report significantly stronger Q2 revenue growth of 29.8% YoY and 15% sequentially. The bearish outlook is further cemented by NVO's downward revision of its full-year 2025 guidance for revenue, operating profit, and a substantially lower free cash flow forecast. This downgrade pushes the forward Price/FCF ratio to a high of 35, more than double the sector median of 14, indicating a stretched valuation that appears disconnected from the company's weakening fundamentals. While NVO's strong balance sheet provides strategic flexibility for M&A or R&D, the current operational trajectory suggests the peak growth phase fueled by its flagship obesity drugs may be over.

Key Decisions for Investors

• Given the decelerating growth and evidence of market share loss to Eli Lilly, investors should treat LLY's upcoming earnings as a critical benchmark for NVO's competitive standing.
• The stock's high forward Price-to-FCF multiple of 35, based on newly lowered guidance, suggests significant downside risk if growth continues to slow, warranting a re-evaluation of positions predicated on high-growth assumptions.
• Monitor for a wave of analyst downgrades to price targets in the coming weeks, as the revised FCF outlook may not yet be reflected in the current optimistic consensus, potentially creating further selling pressure.
• Scrutinize future reports for trends in sales and distribution costs, as continued margin compression from promotional spending is a key risk to profitability and shareholder value.